Screener
BioCryst Pharmaceuticals BCRX Business Segments — Interest Income, Operating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOperating.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Sales and marketing (excluding stock-based compensation) | 33,947 | 45,589 | 76,900 | 93,259 |
| General and administrative (excluding stock-based compensation) | 20,810 | 29,817 | 63,203 | 51,776 |
| Stock-based compensation | 14,692 | 21,304 | 30,719 | 42,672 |
| Interest income | (2,434) | (2,516) | (4,690) | (5,540) |
| Interest expense | 21,712 | 21,582 | 41,491 | 45,076 |
| Foreign currency (gains) losses | (27) | 63 | 198 | 62 |
| Loss on extinguishment of debt | — | 4,171 | — | 4,171 |
| Other (income) expense, net | (260) | — | 1,202 | — |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's business segments — interest income, operating?
- BioCryst Pharmaceuticals (BCRX) reported business segments — interest income, operating of $2.43M in Q2 2026.
- How has BioCryst Pharmaceuticals's business segments — interest income, operating changed year-over-year?
- BioCryst Pharmaceuticals's business segments — interest income, operating decreased by 3.3% year-over-year, from $2.52M to $2.43M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — interest income, operating?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's business segments — interest income, operating has grown at a -17.8% compound annual growth rate (CAGR), from $15.78M to $10.67M.
- What does business segments — interest income, operating mean?
- Includes interest earned on cash balances, cash equivalents, and marketable securities held by the segment. It reflects the segment's ability to generate supplemental income from its liquid assets.
Ask your AI about BioCryst Pharmaceuticals's business segments — interest income, operating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude